天然产物 糖类和糖苷 Saccharides and Glycosides
Pulsatilla saponin D;(Synonyms: SB365; Hederacolchiside A) 纯度: 98.47%
Pulsatilla saponin D (SB365) 可从 Pulsatilla koreana Nakai 根部分离得到,具有抗癌活性。
Pulsatilla saponin D Chemical Structure
CAS No. : 68027-15-6
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10;mM;*;1 mL in DMSO | ¥3977 | In-stock | |
5 mg | ¥1980 | In-stock | |
10 mg | ; | 询价 | ; |
50 mg | ; | 询价 | ; |
* Please select Quantity before adding items.
Pulsatilla saponin D 相关产品
bull;相关化合物库:
- Natural Product Library Plus
- Bioactive Compound Library Plus
- Apoptosis Compound Library
- Natural Product Library
- Anti-Cancer Compound Library
- Glycoside Compound Library
- Terpenoids Library
- Traditional Chinese Medicine Monomer Library
- Anti-Lung Cancer Compound Library
- Anti-Pancreatic Cancer Compound Library
生物活性 |
Pulsatilla saponin D (SB365), isolated from the root of Pulsatilla koreana Nakai, is an anti-tumor agent[1][2][3][4]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
Pulsatilla saponin D (SB365) shows apoptotic effect accompanied by increased evidence of cleaved caspase-3 and poly (ADP ribose) polymerase[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity Assay[4]
|
||||||||||||||||
体内研究 (In Vivo) |
Pulsatilla saponin D (6.4 mg/kg) exhibits anti-tumor activity in Lewis lung carcinoma model[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||
分子量 |
913.10 |
||||||||||||||||
Formula |
C47H76O17 |
||||||||||||||||
CAS 号 |
68027-15-6 |
||||||||||||||||
中文名称 |
白头翁皂苷 D |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
4deg;C, protect from light *In solvent : -80deg;C, 6 months; -20deg;C, 1 month (protect from light) |
||||||||||||||||
溶解性数据 |
In Vitro:;
DMSO : ≥ 39 mg/mL (42.71 mM) * “≥” means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|